Individual susceptibility to occupational carcinogens: The evidence from biomonitoring and molecular epidemiology studies;Suscettibilità individuale ai cancerogeni occupazionali: Evidenze del monitoraggio biologico e dall'epidemiologia molecolare

Giornale Italiano di Medicina del Lavoro ed Ergonomia

Volumn 26, Issue 4, 2004, Pages 311-321

  Pavanello, S ^a   Clonfero, E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biomarkers; Genetic polymorphisms; Individual susceptibility; Lung cancer; Molecular epidemiology; Occupational exposure to carcinogens

Indexed keywords

ACETYLCYSTEINE; ACYLTRANSFERASE; ALUMINUM; AROMATIC AMINE; BENZENE; BIOLOGICAL MARKER; BLEOMYCIN; CARCINOGEN; COAL TAR; COKE; CYTOCHROME P450; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; MUCONIC ACID; PHENYLMERCAPTURIC ACID; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; STYRENE; TOBACCO SMOKE; UNCLASSIFIED DRUG;

BIOLOGICAL MONITORING; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CASE CONTROL STUDY; CHROMOSOME ABERRATION; CONFERENCE PAPER; DIETARY INTAKE; DNA ADDUCT; DNA DAMAGE; DNA POLYMORPHISM; DNA REPAIR; ENZYME ASSAY; ETHNIC DIFFERENCE; FUME; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HIGH RISK POPULATION; HUMAN; LIFESTYLE; LUNG CANCER; MEDICAL LITERATURE; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; SOOT; URINALYSIS; WORK ENVIRONMENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIET; DISEASE PREDISPOSITION; ENVIRONMENTAL MONITORING; EPIDEMIOLOGY; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LUNG TUMOR; MALE; OCCUPATIONAL DISEASE; REVIEW;

BIOLOGICAL MARKERS; CARCINOGENS, ENVIRONMENTAL; CASE-CONTROL STUDIES; DIET; DISEASE SUSCEPTIBILITY; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL MONITORING; EPIDEMIOLOGY, MOLECULAR; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; LIFE STYLE; LUNG NEOPLASMS; MALE; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 14144254346     PISSN: 15927830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. Haufroid-V; Jakubowski-M; Janasik-B; Ligocka-D; Buchet-JP; Bergamaschi-E; Manini-P; Mutti-A; Ghittori-S; Arand-M; Hangen-N; Oesch-F; Hirvonen-A; Lison-D: Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene. Pharmacogenetics 12: 691-702, 2002.
2. Verdina A., Galati R., Falasca G., Ghittori-S; Imbriani-M; Tomei-F; Marcellini-L; Zijno-A; Del-Vecchio-V; Crebelli-R: Metabolic polymorphisms and urinary biomarkers in subjects with low benzene exposure. J. Toxicol. Env. Heal A. 64: 607-618, 2001.
3. Yang M., Kunugita N., Kitagawa K., Kang SH., Coles B., Kadlubar FF, Katoh T., Matsuno K., Kawamoto T. Individual Differences in Urinary Cotinine Levels in Japanese Smokers: Relation to Genetic Polymorphism of Drug-metabolizing Enzymes Cancer Epidemiol Biomarkers Prev 2001 10: 589-593.
4. Pavanello S: Metabolic and DNA repair variations in susceptibility to genotoxins. Polycyclic-Aromatic-Compounds. 2003; 23 (1): 49-10.
5. Rojas, M., Alexandrov, K., Cascorbi, I., Brockmöller, J., Likhachev, A., Pozharisski, K., Bouvier, G., Auburtin, G., Mayer, L., Kopp-Schneider, A., Roots, I., and Bartsch, H. High benzo(a)pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0*0 genotypes. Pharmacogenetics 8: 109-118, 1998.
6. Palli-D; Vineis-P; Russo-A; Berrino-F; Krogh-V; Masala-G; Munnia-A; Panico-S; Taioli-E; Tumino-R; Garte-S; Peluso-M Diet, metabolic polymorphisms and DNA adducts: The EPIC-Italy cross-sectional study International-Journal-of- Cancer. Aug 1, 2000; 87 (3): 444-451.
7. Pavanello S., Pulliero A., Siwinska E., Mielzynska D., and Clonfero E. Genetic variations in GSTM1, nucleotide excision repair and apoptotic capacity on anti-BPDE-DNA adduct levels in mononuclear white blood cells of highly PAH-exposed coke-oven workers. Disease Markers 2004; 20: 27.
8. Wong-RH; Du-CL; Wang-JD; Chan-CC; Luo-JCJ; Cheng-TJ: XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidem. Biomar. Prev. 2002; 11: 475-482.
9. Somorovska-M; Jahnova-E; Tulinska-J; Zamecnikova-M; Sarmanova-J; Terenova-A; Vodickova-L; Liskova-A; Vallova-B; Soucek-P; Hemminki-K; Norppa-H; Hirvonen-A; Tates-AD; Fuortes-L; Dusinska-M; Vodicka-P Biomonitoring of occupational exposure to styrene in a plastics lamination plant Mutation-Research-Fundamental-and-Molecular-Mechanisms-of-Mutagenesis. Jul 16 1999; 428 (1-2): 255-269.
10. Vodicka-P; Soucek-P; Tates-AD; Dusinska-M; Sarmanova-J; Zamecnikova-M; Vodickova-L; Koskinen-M; de-Zwart-FA; Natarajan-AT; Hemminki-K Association between genetic polymorphisms and biomarkers in styrene-exposed workers Mutat Res 2001; 482 (1-2) SI: 89-103.
11. Abdel-Rahman-SZ; Ammenheuser-MM; Ward-JB: Human sensitivity to 1,3-butadiene: role of microsomal epoxide hydrolase polymorphisms. Carcinogenesis MAR 2001; 22 (3): 415-423.
12. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000 Jun 7; 92(11): 874-97.
13. Tang, D., Phillips, D.H., Stampfer, M. et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res., 2001; 61, 6708-6712.
14. Perera FP, Mooney LA, Stampfer M, Phillips DH, Bell DA, Rundle A, Cho S, Tsai WY, Ma J, Blackwood A, Tang D; Physicians' Health Cohort Study. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study. Carcinogenesis. 2002 Oct; 23(10): 1641-1646.
15. Sai-Mei Hou, Susann Fält, Sabrina Angelini, Ke Yang, Fredrik Nyberg, Bo Lambert, and Kari Hemminki The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23: 599-603.
16. Vulimiri SV, Wu X, Baer-Dubowska W, de Andrade M, Detry M, Spitz MR, DiGiovanni J. Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo-2′- deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. Mol. Carcinogen., 2000; 27, 34-46.
17. Gackowski D, Speina E, Zielinska M, Kowalewski J, Rozalski R, Siomek A, Paciorek T, Tudek B, Olinski R. Products of oxidative DNA damage and repair as possible biomarkers of susceptibility to lung cancer. Cancer Res. 2003 Aug 15; 63(16): 4899-4902.
18. Hagmar L, Stromberg U, Bonassi S, Hansteen IL, Knudsen LE, Lindholm C, Norppa H. Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts. Cancer Res. 2004 Mar 15; 64(6): 2258-63.
19. Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of MPO, GSTM1 and GSTT1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003 Oct; 206(6): 473-83.
20. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003 Aug 20; 95(16): 1211-8.
21. Dialyna IA, Miyakis S, Georgatou N, Spandidos DA. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep. 2003 Nov-Dec; 10(6): 1829-35.
22. Quinones L, Lucas D, Godoy J, Caceres D, Berthou F, Varela N, Lee K, Acevedo C, Martinez L, Aguilera AM, Gil L. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 2001 Dec 10; 174(1): 35-44.
23. Song N, Tan W, Xing D, Lin D. CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001 Jan; 22(1): 11-6.
24. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis. 1998 May; 19(5): 813-7.
25. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stucker I, Sugimura H, Taioli E. Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control. 2003 May;14(4): 339-46.
26. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, Kihara M, Kiyohara C, Kremers P, Le Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P, Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer. 2003 May 1; 104(5): 650-7.
27. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Kalina I, Kremers P, Le Marchand L, London S, Rannug A, Romkes M, Schoket B, Seidegard J, Strange RC, Stucker I, To-Figueras J, Garte S. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol. 2003; 32(1): 60-3.
28. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. 2003 Nov 15; 63(22): 8057-61
29. Wang J, Deng Y, Li L, Kuriki K, Ding J, Pan X, Zhuge X, Jiang J, Luo C, Lin P, Tokudome S. Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci. 2003 May; 94(5): 448-52.
30. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers. 2002 May-Jun;7(3): 230-41.
31. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis. 2001 Jun; 22(6): 923-8.
32. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer. 2001; 33(2-3): 133-41.
33. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra-Torres CH, Salama SA, Alpard SK, Tyring SK. Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genet Cytogenet. 2003 Sep; 145(2): 97-102.
34. Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K, Bartsch H, Risch A. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002 Dec 10; 102(5): 530-5.
35. Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC. Counterpoint: the myeloperoxidase -463G→a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12): 1555-9.
36. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S. Point: myeloperoxidase -463G → a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12): 1550-4.
37. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn GB, Whitehead LW, Wu X. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002 Jul; 37(1): 35-40.
38. Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. Am J Ind Med. 2002 Jul; 42(1): 29-37.
39. Stucker I, Boffetta P, Antilla S, Benhamou S, Hirvonen A, London S, Taioli E. Lack of interaction between asbestos exposure and glutathione S-transferase M1 and T1 genotypes in lung carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2001 Dec; 10(12): 1253-8.
40. Ford JG, Li Y, O'Sullivan MM, Demopoulos R, Garte S, Taioli E, Brandt-Rauf PW. Glutathione S-transferase M1 polymorphism and lung cancer risk in African-Americans. Carcinogenesis. 2000 Nov; 21(11): 1971-5.
41. Schneider J, Bernges U, Philipp M, Woitowitz HJGSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett. 2004 May 10;208(1):65-74.
42. Ruano-Ravina A, Figueiras A, Loidi L, Barros-Dios JM. GSTM1 and GSTT1 polymorphisms, tobacco and risk of lung cancer: a case-control study from Galicia, Spain. Anticancer Res. 2003; 23(5b): 4333-7.
43. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmoller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stucker I, To-Figueras J, Brennan P, Taioli E. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis. 2002 Aug;23(8):1343-50.
44. Chen S, Xue K, Xu L, Ma G, Wu J. Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res. 2001 Jun; 458(1-2): 41-7.
45. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer. 2003 Oct 20; 107(1): 139-44.
46. Lan Q, He X. Molecular epidemiological studies on the relationship between indoor coal burning and lung cancer in Xuan Wei, China. Toxicology. 2004, 198(1-3):301-5.
47. Nazar-Stewart V, Vaughan TL, Stapleton P, Van Loo J, Nicol-Blades B, Eaton DL. A population-based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer. Lung Cancer. 2003 Jun; 40(3): 247-58.
48. Wang J, Deng Y, Cheng J, Ding J, Tokudome S. GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. Cancer Lett. 2003 Nov 25; 201(2): 185-93.
49. Miller DP, Neuberg D, de Vivo I, Wain JC, Lynch TJ, Su L, Christiani DC. Smoking and the risk of lung cancer: susceptibility with GSTPI polymorphisms. Epidemiology. 2003 Sep; 14(5): 545-51.
50. Stucker I, Hirvonen A, de Waziers I, Cabelguenne A, Mitrunen K, Cenee S, Koum-Besson E, Hemon D, Beaune P, Loriot MA. Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. Carcinogenesis. 2002 Sep; 23(9): 1475-81.
51. Xu L. L., Wain J. C., Miller D. P., Thurston S. W., Su L., Lynch T. J., Christiani D. C. The NAD(P)H: quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol. Biomark. Prev., 10: 303-309, 2001.
52. Lin P, Hsueh YM, Ko JL, Liang YF, Tsai KJ, Chen CY. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer. 2003 May; 40(2): 123-9.
53. Sunaga N, Kohno T, Yanagitani N, Sugimura H, Kunitoh H, Tamura T, Takei Y, Tsuchiya S, Saito R, Yokota J. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev. 2002 Aug; 11(8): 730-8
54. Liang G, Miao X, Zhou Y, Tan W, Lin D. A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis. 2004 May; 25(5): 773-8.
55. Sugimura H., Kohno T., Wakai K., Nagura K., Genka K., Igarashi H., Morris B. J., Baba S., Ohno Y., Gao C., Li Z., Wang J., Takezaki T., Tajima K., Varga T., Sawaguchi T., Lum J. K., Martinson J. J., Tsugane S., Iwamasa T., Shinmura K., Yokota J. hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol. Biomark. Prev., 8: 669-674, 1999.
56. Le Marchand L., Donlon T., Lum-Jones A., Seifried A., Wilkens L. R. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol. Biomark. Prev., 11: 409-412, 2002.
57. Ito H, Hamajima N, Takezaki T, Matsuo K, Tajima K, Hatooka S, Mitsudomi T, Suyama M, Sato S, Ueda R. A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol. 2002 May; 12(3): 258-65.
58. Wu X, Zhao H, Wei Q, Amos CI, Zhang K, Guo Z, Qiao Y, Hong WK, Spitz MR. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 2003 Mar; 24(3): 505-9.
59. Spitz, M.R., Wu, X., Wang, Y., Wang, L.E., Shete, S., Amos, C.I., Guo, Z., Lei, L., Mohrenweiser, H. and Wei, Q. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-1357.
60. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, Lin D. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer. 2003 Jul 10; 105(5): 669-73.
61. Xing D, Tan W, Wei Q, Lin D. Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer. 2002 Nov; 38(2): 123-9.
62. Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, Cho SS. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002 Aug; 23(8): 1321-5.
63. Zhou W., Liu G., Miller D. R, Thurston S. W., Xu L. L., Wain J. C., Lynch T. J., Su L., Christiani D. C. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res., 62: 1377-1381, 2002
64. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004; 44(1): 74-82.
65. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis. 2000 Aug; 21(8): 1527-30.
66. David-Beabes G. L., London S. J. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer, 34: 333-339, 2001.
67. Divine K. K., Gilliland F. D., Crowell R. E., Stidley C. A., Bocklage T. J., Cook D. L., Belinsky S. A. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res, 2001; 461: 273-278.
68. Park J. Y., Lee S. Y., Jeon H. S., Bae N. C., Chae S. C., Joo S., Kim C. H., Park J. H., Kam S., Kim I. S., Jung T. H. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol. Biomark. Prev 2002; 11: 23-27.
69. Zhou W., Liu G., Miller D. P., Thurston S. W., Xu L. L., Wain J. C., Lynch T. J., Su L., Christiani D. C. Polymorphisms in the DNA Repair Genes XRCC1 and ERCC2, Smoking, and Lung Cancer Risk. Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 359-365.
70. Li D, Firozi PF, Wang LE, Bosken CH, Spitz MR, Hong WK, Wei Q. Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. Cancer Res. 2001 Feb 15; 61(4): 1445-50.
71. Paz-Elizur T, Krupsky M, Blumenstein S, Elinger D, Schechtman E, Livneh Z. DNA repair activity for oxidative damage and risk of lung cancer. J Natl Cancer Inst. 2003 Sep 3; 95(17): 1312-9.
72. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8): 689-98.
73. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003 Oct; 42(1): 1-8.
74. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004; 109(3): 353-6.
75. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004 Feb; 25(2): 229-35.
76. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003 Sep; 24(9): 1499-503.
77. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001 Nov 1; 61(21): 7825-9.
78. Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res, 2002 Nov 15; 62(22): 6430-3.
79. Seifart C, Seifart U, Plagens A, Wolf M, von Wichert P. Surfactant protein B gene variations enhance susceptibility to squamous cell carcinoma of the lung in German patients. Br J Cancer. 2002 Jul 15; 87(2): 212-7.
80. Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. Lung Cancer. 2004 Jan; 43(1): 1-5.
81. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 2000 Dec; 30(3): 153-60.
82. Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer. 2004 Jan 1; 108(1): 109-14.
83. Stellman SD, Takezaki T, Wang L, Chen Y, Citron ML, Djordjevic MV, Harlap S, Muscat JE, Neugut AI, Wynder EL, Ogawa H, Tajima K, Aoki K. Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev 2001 Nov; 10(11): 1193-9.